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S U M M A R Y
Background: Tuberculous meningitis (TBM) is a growing problem in HIV-infected patients in developing
countries, where there is scarce data about this co-infection. Our objectives were to analyze the main
features and outcomes of HIV-infected patients with TBM.
Methods: This was a retrospective study of HIV-infected Brazilian patients admitted consecutively for
TBM. All patients hadMycobacterium tuberculosis isolated from the cerebrospinal ﬂuid (CSF). Presenting
clinical and laboratory features were studied. Multivariate analysis was used to identify variables
associated with death during hospitalization and at 9 months after diagnosis. Survival was estimated
using the Kaplan–Meier method.
Results: We included 108 cases (median age 36 years, 72% male). Only 15% had fever, headache, and
meningeal signs simultaneously. Forty-eight percent had extrameningeal tuberculosis. The median
CD4+ cell count was 65 cells/ml. Among 90 cases, 7% had primary resistance to isoniazid and 9%
presented multidrug-resistant strains. The overall mortality during hospitalization was 29% and at 9
months was 41%. Tachycardia and prior highly active antiretroviral therapy (HAART) were associated
with 9-month mortality. The 9-month survival rate was 22% (95% conﬁdence interval 12–43%).
Conclusions: Clinical and laboratory manifestations were unspeciﬁc. Disseminated tuberculosis and
severe immunosuppression were common. Mortality was high and the 9-month survival rate was low.
Tachycardia and prior HAART were associated with death within 9 months of diagnosis.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Tuberculous meningitis (TBM) is the most severe clinical
presentation of tuberculosis and causes high mortality and
morbidity, particularly in HIV-infected patients.1,2 Despite recent
medical advances, the early diagnosis of TBM continues to be
difﬁcult, and, in daily practice, clinical and cerebrospinal ﬂuid (CSF)
abnormalities usually determine the initiation of empirical
treatment.3 Data of large series from developing countries
regarding conﬁrmed TBM are scarce. This study was performed
in order to describe the clinical presentation and CSF ﬁndings, as
well as to identify the factors associated with mortality, in HIV-* Corresponding author. Tel.: +55 11 38812834; fax: +55 11 31205290.
E-mail address: josevibe@gmail.com (J.E. Vidal).
1201-9712/$36.00 – see front matter  2009 International Society for Infectious Disea
doi:10.1016/j.ijid.2009.08.012infected patientswith culture-proven TBM from a referral center in
Sao Paulo, Brazil.
2. Materials and methods
We retrospectively analyzed data from the clinical records of
all HIV-infected patients with a diagnosis of TBM admitted
between March 1999 and December 2007 to the Emı´lio Ribas
Institute of Infectious Diseases, Sao Paulo, Brazil. Our hospital is
a 250-bed tertiary teaching center that serves a population of
low socio-economic level from Sao Paulo State. All clinical
records were reviewed for the period from TBM diagnosis to 9
months after diagnosis. HIV infection was diagnosed by enzyme-
linked immunosorbent assay (ELISA) and conﬁrmed by western
blotting. The diagnosis of TBM was based on the presence of at
least one culture showing growth of Mycobacterium tuberculosisses. Published by Elsevier Ltd. All rights reserved.
Table 1
Clinical and laboratory characteristics of 108 HIV-infected patients with conﬁrmed
tuberculous meningitis
Variable Patients (N=108)
Age, median (range) years 36 (6–53)
Male, n (%) 78 (72)
Symptoms at presentation, n (%)
Headache 82 (76)
Nausea 41 (38)
Altered mentation 38 (35)
Focal deﬁcit 17 (16)
Seizures 12 (11)
Signs at presentation, n (%)
Fever 84 (78)
Meningeal signs 20 (19)
Hepatomegaly 25 (23)
Splenomegaly 16 (15)
Adenopathy 10 (9)
BMRC severity grade, n (%)
I 40 (37)
II 43 (40)
III 25 (23)
Extrameningeal tuberculosis, n (%) (N=107) 52 (48)
Prior TB, n (%) 63 (58)
CT abnormalities, n (%) (N=100) 55 (55)
Prior HAART, n (%) (N=103) 63 (61)
HAART at admission, n (%) (N=71) 36 (51)
Hemoglobin level, median (range) mg/dl 11 (6–16.9)
CD4+ cell count, median (range) cells/ml (N=98) 65 (2–624)
BMRC, British Medical Research Council staging system; TB, tuberculosis; CT,
computed tomography scan; HAART, highly active antiretroviral therapy.
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clinical (signs and symptoms), and laboratory (CSF results,
hemoglobin, cultures and susceptibility proﬁle to M. tuberculo-
sis) information using a standardized questionnaire. The
neurologic status of patients was classiﬁed according to the
British Medical Research Council (BMRC) staging system, which
grades TBM as follows: grade I, patient with non-speciﬁc
symptoms and signs, no clouding of consciousness, and no
neurologic deﬁcits; grade II, patient with lethargy or behavioral
changes, meningeal irritation, or minor neurologic deﬁcits such
as cranial nerve palsies; and grade III, patient with stupor or
coma, abnormal movements, seizures or severe neurologic
deﬁcits such as paresis.4 CSF with the presence of pleocytosis
(>5 cells/ml), high protein levels (>45 mg/dl), and low glucose
levels (<45 mg/dl) was considered ‘typical’ of TBM. We deﬁned
primary drug resistance as resistance found in patients
previously untreated with anti-tuberculosis drugs. Multidrug-
resistant (MDR) tuberculosis was deﬁned as a strain of M.
tuberculosis with documented resistance in vitro to at least
isoniazid and rifampin. Drug susceptibility testing data were
retrieved from the registries of the Mycobacteriology Laborato-
ry, Adolfo Lutz Institute, a reference laboratory in Sao Paulo,
Brazil. Information on mortality was obtained from the clinical
records.
At our institution, the treatment of tuberculosis in HIV-infected
patients follows the guidelines of the Ministry of Health of Brazil.5
Therefore, the initial TBM treatment is 2 months of daily oral
isoniazid (10 mg/kg), rifampin (10 mg/kg) and pyrazinamide
(35 mg/kg), followed by 7 months of oral isoniazid and rifampin
at the same dosages. Corticosteroids were used for 1–2 months
(prednisone 1 mg/kg/day).
Continuous variables were described with medians and
ranges; categorical variables were described with numbers and
percentages. Variables with < 20% missing values were imputed
using simple imputation (EM method from SPSS; SPSS Inc.,
Chicago, IL, USA). Variables were compared with the Wilcoxon
rank sum test or Fisher’s exact test, as appropriate. The primary
outcome was death during hospitalization. The secondary
outcome was death within 9 months of presentation. We
evaluated patient characteristics associated with the primary
and secondary outcomes. The Cox proportional hazards model
was used as the primary model. Variables associated with the
outcome with a p-value of 0.5 in the univariate analysis were
included in the multivariate analysis. Variables associated with
the outcome with a p-value of 0.05 in the multivariate analysis
remained in the model. Survival distribution was estimated using
the Kaplan–Meier method. The comparison of survival between
the different subject groups was performed by log-rank test.
Overall, a p-value of 0.05 denoted a statistical association. SPSS
11.0 was used for all calculations. The study was approved by the
ethical and scientiﬁc boards of the Emı´lio Ribas Institute of
Infectious Diseases.
3. Results
3.1. Clinical and laboratory characteristics
Of the 108 cases included in the study, 78 (72%) were male and
the median age was 36 years. Sixty-three (58%) patients presented
a history of prior tuberculosis, six of them with neurological
involvement. Sixty-three (61%) of 103 patients with available
information had previously used at least one antirretroviral
combination, and 36 (51%) of 71 patients with available informa-
tionwere using antiretrovirals at the time of admission. In hospital,
52 (48%) patients were diagnosed with concomitant extramenin-
geal tuberculosis: 35 cases with pulmonary involvement, 11 withlymphatic involvement, and six cases with blood involvement
(deﬁned by growth ofM. tuberculosis in cultures of blood samples).
The main clinical and laboratory features of the patients are
showed in Table 1.
The classic triad of fever, headache, and meningeal signs was
described in only 16 (15%) patients. Fever and headache were
simultaneously present in 65 (60%) cases. The CSF cell count (total
leukocyte count, 106/l) was categorized as follows: 5 (nor-
mal) = 20 (19%) patients; 6–100 = 28 (26%) patients; 101–500 = 45
(42%) patients; >500 = 15 (14%) patients. The CSF patterns
identiﬁed are shown in Table 2. The ‘typical’ CSF alterations of
TBM were observed in 69 patients (64%). In addition, only 13%
showed none or only one altered CSF parameter. In Tables 1 and 2,
the number of patients with information available is speciﬁed
where information was missing for at least one patient. There was
missing information for the following variables: extrameningeal
tuberculosis for one patient (1%), computed tomography (CT)
abnormalities for eight (7%), prior highly active antiretroviral
therapy (HAART) for ﬁve (5%), HAART at admission for 37 (34%),
CD4 at baseline for 10 (9%), CSF:serum glucose ratio for 16 (15%),
in-hospital death for one (1%), follow-up of in-hospital death for
four (4%), and follow-up within 9 months for three (3%). All
analyses were done with those patients with complete informa-
tion.
Drug susceptibility testing was done only for isoniazid,
rifampin, pyrazinamide, ethambutol, and streptomycin. The test
results for isoniazid, rifampin, and pyrazinamide were available in
90 cases and for ethambutol and streptomycin in 77. Fifty-four
(60%) patients were not resistant to any drug. Twenty-one (23%)
patients had resistance to isoniazid, 10 (11%) to rifampin, and ﬁve
(6%) to streptomycin. No resistance to pyrazinamide and
ethambutol was found. Seven (8%) patients presented primary
resistance to isoniazid. Of the eight (9%) patients with MDR
tuberculosis, six had a history of prior tuberculosis and two
presented this resistance pattern at the ﬁrst clinical manifestation
of tuberculosis. No patient had extensively drug-resistant tuber-
culosis (XDR-TB).
Table 3
Patient characteristics associated with death during hospitalization in the
multivariate analysis of 108 HIV-infected patients with conﬁrmed tuberculous
meningitis
Characteristic Multivariate HR (95% CI) p-Value
Age (years) 1.1 (1.0–1.1) 0.2
Headache 0.7 (0.2–2.7) 0.6
Nausea/vomiting 0.3 (0.1–1.2) 0.09
Tachycardia 2.4 (0.2–28.9) 0.06
Meningism 1.5 (0.2–13.8) 0.7
BMRC III vs. I + II 2.4 (0.7–8.0) 0.2
Prior HAART 1.7 (0.5–6.2) 0.4
CD4+ cell count <100 cells/ml 2.4 (0.5–10.4) 0.3
Hemoglobin level <8 g/dl 1.4 (0.2–10.9) 0.7
Resistance to isoniazid 0.6 (0.2–2.1) 0.4
CSF glucose <45 mg/dl 9.8 (1.0–94.3) 0.05
HR, hazard ratio; CI, conﬁdence interval; BMRC, British Medical Research Council
staging system; HAART, highly active antiretroviral therapy; CSF, cerebrospinal ﬂuid.
Table 4
Patient characteristics associated with death within 9 months after diagnosis of
tuberculous meningitis in the multivariate analysis of 108 HIV-infected patients
Characteristic Multivariate HR (95% CI) p-Value
Age (years) 1.0 (1.0–1.1) 0.3
Headache 0.8 (0.3–2.5) 0.8
Nausea/vomiting 0.8 (0.3–2.0) 0.6
Tachycardia 9.8 (1.4–69.5) 0.02
Meningism 1.9 (0.5–7.3) 0.3
BMRC III vs. I + II 1.4 (0.5–3.8) 0.5
Prior HAART 3.2 (1.1–9.6) 0.04
CD4+ cell count <100 cells/ml 2.6 (0.8–9.0) 0.1
Hemoglobin level <8 g/dl 2.4 (0.4–15.1) 0.4
Resistance to isoniazid 1.2 (0.4–3.1) 0.8
CSF glucose <45 mg/dl 3.2 (0.9–10.8) 0.06
HR, hazard ratio; CI, conﬁdence interval; BMRC, British Medical Research Council
staging system; HAART, highly active antiretroviral therapy; CSF, cerebrospinal
ﬂuid.
Figure 1. Kaplan–Meier graph showing the probability of survival of HIV-infected
patients with tuberculous meningitis (dotted lines are 95% conﬁdence intervals).
Table 2
Cerebrospinal ﬂuid ﬁndings of 108 HIV-infected patients with conﬁrmed
tuberculous meningitis
Patients (N=108)
CSF ﬁndings, median (range)
Total leukocyte count, 106/l 160 (1–2880)
Neutrophils 44 (0–100)
Lymphocytes 49 (0–100)
Monocytes 7 (1–43)
CSF glucose (mg/dl) 29 (7–117)
CSF:blood glucose ratio (N=92) 0.27 (0.06–1.01)
Protein (mg/dl) 171 (19–1249)
CSF patterns, n (%)
3 altered parameters 69 (64)
2 altered parameters 25 (23)
Glucose and protein 7
Total leukocyte count and protein 15
Total leukocyte count and glucose 3
1 altered parameter 10 (9)
Total leukocyte count 2
Glucose 2
Protein 6
None 4 (4)
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patients with and without HAART use on admission. Nausea (11
(33%) vs. 20 (57%) cases, p = 0.03), focal deﬁcit (nine (25%) vs. two
(6%) cases, p = 0.03), and prior HAART use (23 (64%) vs. 25 (71%)
cases, p = 0.004) were more frequent in the group with HAART use
on admission. In addition, the median (range) CD4 cell count was
similar among patients with and without HAART use on admission
(76 (11–624) vs. 70 (2–237) cells/ml, p = 0.4).
4. Characteristics associated with mortality
Also, the text states earlier that ‘‘There was missing
information for the following variables:. in-hospital death for
one (1%), follow-up of in-hospital death for four (4%), and follow-
up within 9 months for three (3%).’’ This would then give 44/
105=42% (remove 3 missing 9-month follow-up) or 44/101=44%
(remove 3 missing 9-month follow-up and 4 missing in-hospital
follow-up).
Is 41% correct? 44/108 gives 41%, however removing 7 cases
lost to follow-up gives 44/101=44%.
The overall mortality during hospitalization was 29% (31
patients) and the overall 9-monthmortality was 41% (44 patients),
excluding the seven cases that were lost to follow-up. AmongMDR
cases, the mortality during hospitalization was 38% (three
patients) and the overall 9-month mortality was 71% (ﬁve
patients), excluding one patient who was lost to follow-up.
Headache (hazard ratio (HR) 0.4, 95% conﬁdence interval (CI) 0.2–
0.8, p = 0.01), nausea/vomiting (HR 0.3. 95% CI 0.1–0.8, p = 0.01),
and hemoglobin <8 mg/dl (HR 3.2, 95% CI 1.2–8.4, p = 0.02) were
associated with death during hospitalization in the univariate
analysis. Isoniazid resistance (HR 1.0, 95% CI 0.4–2.5, p = 0.9) and
MDR tuberculosis (HR 0.9, 95% CI 0.3–3.0, p = 0.8) were not
associated with death during hospitalization in the univariate
analysis. None of the variables remained associatedwhen included
in themultivariatemodel (Table 3). However, CSF glucose<45 mg/
dl (HR 3.2, 95% CI 0.9–10.8, p = 0.06) presented a borderline
association.
Headache (HR 0.5, 95% CI 0.2–0.9, p = 0.01), tachycardia (HR 6.2,
95% CI 2.1–18.1, p < 0.01), and CD4+ cell count <100 cells/ml (HR
2.5, 95% CI 1.1–5.7, p = 0.03) were associated with death within 9
months after TBMdiagnosis in the univariate analysis. Prior HAART
(HR 2.1, 95% CI 1.0–4.1, p = 0.04), BMRC III vs. I + II (HR 1.9, 95% CI
1.0–3.5, p = 0.06), and hemoglobin <8 mg/dl (HR 2.7, 95% CI 1.0–
8.4, p = 0.04) were marginally associated with death within 9months after TBM diagnosis in the univariate analysis. Isoniazid
resistance (HR 0.4, 95% CI 0.1–1.8, p = 0.3) and MDR tuberculosis
(HR 1.1, 95% CI 0.4–2.8, p = 0.9) were not associated with death
within 9 months of diagnosis in the univariate analysis.
Tachycardia (HR 9.8, 95% CI 1.4–69.5, p = 0.02) and prior HAART
(HR 3.2, 95% CI 1.1–9.6, p = 0.04) remained associated when
included in themultivariatemodel (Table 4). However, CSF glucose
<45 mg/dl (HR 3.2, 95% CI 0.9–10.8, p = 0.06) presented only a
borderline association.
The estimated median survival time was 3 months (95% CI 2–4
months). The Kaplan–Meier estimates of the probability of survival
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months, and 22% (95% CI 12–43%) at 9 months. Figure 1 shows the
overall cumulative probability of survival of patients with TBM.
5. Discussion
The present study retrospectively assessed the clinical and
laboratory features and factors associated with mortality in 108
HIV-infected patients with culture-positive TBM in Sao Paulo,
Brazil. Overall, the mortality during hospitalization was 29% and
within 9 months was 41%. Only tachycardia and prior HAART use
were associated with death within 9 months in the multivariate
analysis.
Tuberculosis is a prevalent and challenging problem in
developing countries, including Brazil, and TBM is the most
frequent neurologic complication. In our setting, TBM constitutes
the thirdmost frequent neurologic opportunistic condition and it is
only exceeded by cerebral toxoplasmosis and cryptococcal
meningoencephalitis.6,7 In addition, TBM represents the second
most frequent cause of opportunisticmeningitis in AIDS patients in
Brazil.8
TBM continues to cause high mortality rates in HIV-infected
patients, particularly those in developing countries, due in part to
late diagnosis. The clinical presentation is usually non-speciﬁc and
similar to other neurologic opportunistic infections such as
cryptococcosis, neurosyphilis, and bacterial meningitis. Therefore,
a high index of suspicion should always be maintained, and
computerized tomography and lumbar puncture (in the absence of
contraindications) should be performed.
In clinical practice, determining the initiation of anti-tubercu-
lous agents is challenging, especially in resource-limited settings,
where diagnosis tools such as PCR are usually unavailable. In this
regard, considering that only 15% of cases presented the classic
triad of fever, headache, andmeningeal signs, it is necessary to take
advantage of CSF ﬁndings. Approximately 64% of our cases
presented the ‘typical’ CSF alterations of TBM, a pattern previously
well deﬁned in the literature.9 In these cases, the presence of
clinical symptoms and the exclusion of other etiologies of
meningitis should lead to a prompt initiation of anti-tuberculous
treatment. On the other hand, the presence of none or only one
altered parameter, observed in 13% of our cases, should call for a
more conservative approach, always considering each clinical
context. Interestingly, 18% of cases presented a normal total
leukocyte count and 5% of cases had only high protein and low
glucose simultaneously. The absence of pleocytosis has previously
been described in 11–16% of HIV-infected patients with TBM.10,11
In the present study, approximately 50% of cases had extraneural
tuberculosis, occurring particularly in the lung. Similarly, previous
studies have reported the isolation of M. tuberculosis from
extraneural samples in 55–77% of cases,12,13 conﬁrming the high
rate of disseminated tuberculosis in HIV-infected patients.
Furthermore, an intensive investigation of extrameningeal tuber-
culosis should be performed in all possible cases of TBM.
In the present series, 9% of patients had MDR TBM and most of
them (75%) presented a history of previous tuberculosis. A study
performed in a hospital that assists a marginalized population,
reported 42 (42%) patients with MDR TBM among 101 HIV-
infected patients with TBM, and 43% of cases had previously
undergone incomplete treatment or were taking anti-tuberculous
drugs at the time of TBM diagnosis.12 Another study reported 30
(9%) patients with MDR TBM among 350 patients (HIV-positive
and -negative) with TBM. The frequency of cases with a history of
tuberculosis treatment among the HIV-infected patients withMDR
TBMwas high (89%).14 Another study showed 10 (6%) patientswith
MDR TBM among 180 patients (HIV-positive and -negative) with
TBM; in this study, HIV infection was independently associatedwith MDR TBM.15 Considering the high prevalence of MDR TBM in
developing countries and that MDR TBM is strongly predictive of
death,15 it is necessary to consider the history of previous
tuberculosis treatment in all HIV-infected patients with a
suspicion of TBM, and to highlight the need to evaluate the
susceptibility proﬁle in order to choose the best anti-tuberculous
treatment.
The present study is the ﬁrst to show the high resistance proﬁle
of TBM in HIV-infected patients in Sao Paulo. An ofﬁcial report
using data of a survey from 1997 indicates that the prevalence of
primary resistance to isoniazid and rifampin in the general
population of Brazil is low (1.1%).16 Current national guidelines
recommend therapeutic schemes with three drugs for initial
pulmonary tuberculosis and TBM in HIV-infected patients.5,17 In
contrast, studies performed in HIV-infected patients from Sao
Paulo have found values of primary resistance to isoniazid of 6.9–
7.1% andMDR resistance of 11.6–16.6%.18,19We consider that this
information taken together with our results showing that 7% of
HIV-infected patients with TBM presented primary resistance to
isoniazid, suggests that the use of three drugs should be revisited
in our setting. Therefore, it appears reasonable to include
ethambutol until susceptibility tests are available. Updated
epidemiologic surveys will give a more deﬁnite answer to this
issue.
TBM is a fatal disease without treatment, causing death in 30–
69% of cases20,21 despite anti-tuberculous treatment, and HIV-
infection signiﬁcantly reduces the survival rate.1 In the present
study, the overall mortality during hospitalizationwas 29% and the
overall 9-month mortality was 41%. Higher rates of mortality in
AIDS-related TBM have been described in other studies. A study
fromZimbabwe reported an in-hospitalmortality of 67% in 21HIV-
infected patients with conﬁrmed TBM.22 A recent survey from
Argentina reported that the globalmortality during hospitalization
among 101 HIV-infected patients with conﬁrmed TBM was 63%.12
Another study from Vietnam with patients recruited to a
randomized controlled trial, reported that the 9-month mortality
rate among 96 HIV-infected patients with deﬁnite, probable, or
possible TBM was 65%.1 In contrast to most resource-limited
settings, we speculate that the availability of HAART in Brazil
probably improved the long-term prognosis, at least in a subset of
our patients. However, TBM continues to cause high mortality and
represents a life-threatening disease, as shown by the estimated
median survival time of 3 months and estimate of the probability
of survival at 9 months of 22% in our study.
In addition, the speciﬁc clinical and laboratory proﬁles of the
patients included in each study seem to explain the differences in
mortality rates. For example, a previous study has reported 81% of
patients with BMRC II and III, 42% of MDR strains, and 63% in-
hospital mortality.12 In contrast, in patients with a similar degree
of immunodeﬁciency, our study reported 64% of cases classiﬁed as
BMRC II and III, 9% of MDR strains, and 29% of in-hospital
mortality.
The patients included in our study had some features that
appear to have contributed to maintaining the high rates of TBM
mortality, despite the availability of a reasonable infrastructure
in our hospital: HIV status, inclusion of only culture-positive
cases, frequency of disseminated tuberculosis, rates of MDR
resistance, and extended (e.g., anemia, malnutrition) and severe
immunosuppression (e.g., low CD4+ cell count).1,9,12,14,15 In
addition, it is possible that the usual limitations of access to
healthcare in developing countries could be an additional reason
for the delayed presentation that we observed in our patients,
who were predominantly persons of low socio-economic level.
Although we did not retrieve the median length of clinical
symptoms before admission, we believe that this was prolonged.
This fact was recently reported in patients with bacterial
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in Malawi.23
Data on prognostic factors of TBM in HIV-infected patients
are scarce. Factors independently associated with death in AIDS-
related TBM include BMRC grade III,1 BMRC grade II or III, CD4+
cell count <50 cells/ml, and MDR strains.12 Tuberculous drug
resistance (when not MDR) is an uncertain inﬂuence on
outcome. Some preliminary unpublished data from Vietnam
suggest that the outcome of isoniazid-resistant TBM is worse
than for the fully sensitive disease (Guy Thwaites, personal
communication). However, in the present study we did not ﬁnd
this association.
In this study, we identiﬁed some variables associated with 9-
month mortality in a multivariate model: tachycardia and prior
HAART use. Most of our patients had severe immunosuppression
and reported previous antiretroviral therapy use. In addition, the
median CD4 cell count was similar among patients with and
without HAART use on admission. Thus, prior HAART use and
further discontinuation or irregular use seem to be the more likely
explanations for the unexpected ﬁnding of prior HAART use and
unfavorable outcome. The loss of opportunity to use HAART has
previously been described in other neurologic complications and
represents a current challenge in Brazil, a developing country
which has had a free and universal access program for HAART since
1996.24,25
Although we did not identify an association between anemia
and mortality, hemoglobin levels are a known risk factor for death
in patients with HIV26,27 and TB infection.28 A study has reported
that the hematocrit level is independently associatedwith death in
HIV-infected patients with TBM.1 Anemia is a surrogate marker for
poor general health in HIV-infected patients from developing
countries, and it is frequently described in patients with
neurological diseases.22,23
We identiﬁed a borderline association between CSF glucose
levels and in-hospital and 9-month mortality. In accordance with
this, the presence of hypoglycorrhachia has been correlated with
the more advanced stages of TBM.9
This retrospective study has several limitations. These include
the absence of a standardized history and neurological examina-
tion that could have resulted in misclassiﬁcation of patients with
regard to neurologic symptoms and signs; the lack of a complete
neurological evaluation at discharge; the absence of an adequate
registry of follow-up data, precluding any inference about
therapeutic aspects (for example, to compare schemes with
three vs. four anti-tuberculous agents, schemes with and without
corticosteroids, and timing and type of antiretrovirals given). In
addition, we included only culture-proven cases and therefore
our results are only applicable to patients who met these strict
diagnosis criteria. Although this is a large series of patients with
TBM for a single institution, the relatively small sample size may
have compromised the power to detect signiﬁcant associations
between patient characteristics and mortality. Finally, we were
not able to identify information about potential cases of TBM in
the setting of immune reconstitution inﬂammatory syndrome.
Only prospective studies could answer this challenging question.
In this series of TBM in HIV-infected patients, the clinical
presentation was unspeciﬁc, disseminated tuberculosis was
common, mortality was high, and most patients had severe
immunosuppression. Tachycardia and prior HAART use were
independently associated with death within 9 months of TBM
diagnosis.
Ethical approval
The study was approved by the ethical and scientiﬁc boards of
the Emilio Ribas Institute of Infectious Diseases.Conﬂict of interest
No conﬂict of interest to declare.
Acknowledgements
We would like to thank Guy E. Thwaites, Centre for Molecular
Microbiology and Infection, Imperial College, London, UK, for
helpful advice and discussions.
References
1. Thwaites GE, Duc Bang N, Huy Dung N, Thi Quy H, Thi Tuong Oanh D, Thi
Cam Thoa N, et al. The inﬂuence of HIV infection on clinical presentation,
response to treatment, and outcome in adults with tuberculous meningitis. J
Infect Dis 2005;192:2134–41.
2. Thwaites GE, Nguyen DB, Nguyen HD, Hoang TQ, Do TT, Nguyen TC, et al.
Dexamethasone for the treatment of tuberculousmeningitis in adolescents and
adults. N Eng J Med 2005;351:1741–51.
3. Thwaites GE, Chau TT, Stepniewska K, Phu NH, Chuong LV, Sinh DX, et al.
Diagnosis of adult tuberculous meningitis by use of clinical and laboratory
features. Lancet 2002;360:1287–92.
4. British Medical Research Council. Streptomycin treatment of tuberculous men-
ingitis. Lancet 1948;1:582–96.
5. Ministe´rio da Sau´de do Brasil. Recomendac¸o˜es para terapia anti-retroviral em
adultos e adolescentes infectados pelo HIV—2007/2008. Available at: http://
www.aids.gov.br (accessed October 2008).
6. Oliveira JF, Greco DB, Oliveira GC, Christo PP, Guimara˜es MD, Oliveira RC.
Neurological disease in HIV-infected patients in the era of highly active antire-
troviral treatment: a Brazilian experience. Rev Soc Bras Med Trop 2006;39:146–
51.
7. Vidal JE, Penalva de Oliveira AC, Fink MC, Pannuti CS. AIDS-related progressive
multifocal leukoencephalopathy: a retrospective study in a referral center in
Sao Paulo, Brazil. Rev Inst Med Trop S Paulo 2008;50:209–12.
8. Trujillo JR, Jaramillo-Rangel G, Ortega-MartinezM, Penalva de Oliveira AC, Vidal
JE, Bryant J, et al. International NeuroAIDS: prospects of HIV-1 associated
neurological complications. Cell Res 2005;15:962–9.
9. Zuger A, Tuberculosis. In: Scheld WM, Whitley RJ, Marra CM, editors. Infections
of the central nervous system. 3rd ed., Philadelphia: Lippincott-Raven; 2004. p.
441–60.
10. Laguna F, Adrados M, Ortega A, Gonzales-Lahiz JM. Tuberculosis
meningitis with acellular cerebrospinal ﬂuid in AIDS patients. AIDS 1992;
6:1165–7.
11. Berenguer J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.
Tuberculousmeningitis in patients infectedwith the human immunodeﬁciency
virus. N Engl J Med 1992;326:668–72.
12. Cecchini D, Ambrosioni J, Brezzo C, Corti M, Rybko A, PerezM, et al. Tuberculous
meningitis in HIV-infected patients: drug susceptibility and clinical outcome.
AIDS 2007;21:373–4.
13. Karstaedt AS, Valtchanova S, Barriere R, Crewe-Brown HH. Tuberculous men-
ingitis in South African urban adults. Q J Med 1998;91:743–7.
14. Patel VB, Padayatchi N, Bhigjee AI, Allen J, Bhagwan B, Moodley AA, et al.
Multidrug-resistant tuberculosis meningitis in KwaZulu-Natal, South Africa.
Clin Infect Dis 2004;38:851–6.
15. Thwaites GE, Lan NT, Dung NH, Quy HT, Oanh DT, Thoa NT, et al. Effect of
antituberculosis drug resistance on response to treatment and outcome in
adults with tuberculous meningitis. J Infect Dis 2005;192:79–88.
16. Braga JU, Barreto AM, Werneck AM, Hijjar MA. Inque´rito Epidemiolo´gico da
resisteˆncia a`s drogas usadas no tratamento da tuberculose no Brasil, 1995–97—
Parte III: principais resultados. Boletim da Campanha Nacional Contra a Tuber-
culose (Rio de Janeiro) 2003;11:76–81.
17. Castelo Filho A, Kritski AL, Barreto AW, Lemos ACM, Rufﬁ no Netto A, Guimara˜es
CA, et al. II Consenso Brasileiro de tuberculose: diretrizes brasileiras para
tuberculose 2004. J Bras Pneumol 2004;30(Suppl 1):1–56.
18. Pinto WP, Hadad DJ, Silva Telles MA, Ueki SY, Palaci M, Basile MA, et al.
Tuberculosis and drug resistance among patients seen at an AIDS reference
center in Sao Paulo, Brazil. Int J Infect Dis 2001;5:93–100.
19. Rozman LM, Santo AH, RozmanMA.Mycobacterium tuberculosis drug resistance
in HIV patients in Baixada Santista, Sao Paulo, Brazil. Cad Saude Publica 2007;
23:1051–9.
20. Thwaites G, Hien TT. Tuberculous meningitis: many questions, too few
answers. Lancet Neurol 2005;4:160–70.
21. Trachtenberg JD, Kambugu AD, McKellar M, Semitala F, Mayanja-Kizza H,
Samore MH, et al. The medical management of central nervous system infec-
tions in Uganda and the potential impact of an algorithm-based approach to
improve outcomes. Int J Infect Dis 2007;11:524–30.
22. Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, et al.
Impact of HIV infection onmeningitis in Harare, Zimbabwe: a prospective study
of 406 predominantly adult patients. AIDS 2000;14:1401–7.
23. Scarborough M, Gordon SB, Whitty CJ, French N, Njalale Y, Chitani A, et al.
Corticosteroids for bacterial meningitis in adults in sub-Saharan Africa. N Engl J
Med 2007;357:2441–50.
M.G. Croda et al. / International Journal of Infectious Diseases 14 (2010) e586–e591 e59124. Vidal JE, Hernandez AV, de Oliveira AC, Dauar RF, Barbosa SP, Focaccia R, et al.
Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and
predictors of treatment response in the HAART era. AIDS Patient Care STDs
2005;19:840–8.
25. Marins JR, Jamal LF, Chen SY, Barros MB, Hudes ES, Barbosa AA, et al. Dramatic
improvement in survival among adult Brazilian AIDS patients. AIDS 2003;
17:1675–82.26. Lundgren JD, Mocroft A. Anemia and survival in human immunodeﬁciency
virus. Clin Infect Dis 2003;37(Suppl 4):297–303.
27. Moore RD, Keruly JC, Chaisson RE. Anemia and survival in HIV infection. J Acquir
Immune Deﬁc Syndr Hum Retrovirol 1998;1:29–33.
28. Klautau GB, Kuschnaroff TM. Clinical forms and outcome of tuberculosis in HIV-
infected patients in a tertiary hospital in Sao Paulo – Brazil. Braz J Infect Dis
2005;6:464–7.
